LIR Life Sciences Corp.
BBCMF
$0.20
$0.000.00%
OTC PK
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -38.91% | 882.41% | |||
| Depreciation & Amortization | -10.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.11% | 881.33% | |||
| Operating Income | 36.11% | -881.33% | |||
| Income Before Tax | 35.92% | -1,029.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.92% | -1,029.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.92% | -1,029.82% | |||
| EBIT | 36.11% | -881.33% | |||
| EBITDA | 36.14% | -887.68% | |||
| EPS Basic | 37.15% | -689.04% | |||
| Normalized Basic EPS | 42.93% | -700.00% | |||
| EPS Diluted | 37.15% | -689.04% | |||
| Normalized Diluted EPS | 42.93% | -700.00% | |||
| Average Basic Shares Outstanding | 1.89% | 42.75% | |||
| Average Diluted Shares Outstanding | 1.89% | 42.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||